medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2013, Number 2

<< Back

Rev Mex Patol Clin Med Lab 2013; 60 (2)

Late-onset hypogonadism in patients with diabetes mellitus and sexual dysfunction

Elías-Calles LC, Calero RJL, Licea PME

Language: Spanish
References: 47
Page: 116-123
PDF size: 67.45 Kb.


ABSTRACT

Background: Late-onset hypogonadism is more common in individuals with type 2 diabetes mellitus that in the general population. Objectives: To determine the frequency of late-onset hypogonadism in adult males with type 2 diabetes mellitus and erectile sexual dysfunction. Methods: An observational, descriptive study in diabetic men attending the Andrology Consultation Diabetes Care Center at the National Institute of Endocrinology between January 2008 and December 2012. In 283 medical records we studied clinical, biochemical and hormonal variables . Results: Of the sample, 76.3% had late-onset hypogonadism. Age, duration of diabetes mellitus, smokers and diabetic neuropathy was higher in hypogonadal. Hypogonadism is associated with body mass index, waist circumference and waist-hip ratio. Conclusions: chronological age, age at diagnosis of type 2 diabetes mellitus, body mass index, waist circumference, hip circumference, smoking, presence of hypertension and diabetic peripheral neuropathy is associated with the presence of late-onset hypogonadism. There is no association between hypogonadism and severity of sexual erectile dysfunction.


REFERENCES

  1. Alfonso JC. Experiencias de países. El caso de Cuba. En: Seminario Regional “Envejecimiento, Políticas Públicas y Desarrollo en América Latina. Retos presentes, necesidades futuras”. Cuaderno de Estudio de Población y Desarrollo 2010. CEPDE/ONE. La Habana, 2010.

  2. Peláez M. La construcción de las bases de la buena salud en la vejez: situación en las Américas. Rev Panam Sal Publ. 2005; 175 (6): 299-302.

  3. Sánchez I. Características de la diabetes tipo 2 en el adulto mayor. Tesis de Maestría para optar por el Título de Máster en Longevidad Satisfactoria. Instituto Superior de Ciencias Médica. Facultad de Ciencias Médicas “10 de Octubre”. Ciudad de la Habana, 2010.

  4. MINSAP. Anuario Estadístico de Salud 2011. Dirección Nacional de Registros Médicos y Estadísticas de Salud. La Habana: MINSAP; 2011.

  5. Bhasin SH. Testicular disorders. In: Williams Textbook of Endocrinology. 11th ed. Philadelphia: Elsevier; 2008. p. 645-672.

  6. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 5462–5468.

  7. Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Internat J Imp Res. 2003; 15 (suppl 4): S14–S20.

  8. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care. 2002; 25: 55-63.

  9. J Gooren. Late-onset hypogonadism. Front Horm Res. 2009; 37: 62-73.

  10. Morales A. Testosterone deficiency syndrome in males: science and politics. Eur Urol. 2007; 6: 851-859.

  11. Laughlin GA, Barrett-Connor E, Bergstrom J. Low Serum Testosterone and Mortality in Older Men. J Clin Endocrinol Metab. 2008; 93: 68-75.

  12. Wu FCW, Tajar A, Pye SR et al. Hypothalamic–pituitary–testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008; 93: 2737–2745.

  13. Rosenfelt V. Andropausia o deficiencia androgénica del adulto mayor. Rev Med Clín Condes. 2009; 20: 161-165.

  14. Maurizio Buscarini, Antonio Cardi. Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review. World Int Urol Nephrol. 2010; 17: 167-173.

  15. Wang C, Nieschlag E, SwerdLoff R et al. Investigation, treatment,and monitoring of late-onset hypogonadism in males: ISA, ISSAM,EAU, EAA, and ASA recommendations. J Androl. 2009; 30: 1-9.

  16. Bassil N. Late-onset hypogonadism. Med Clin North Am. 2011; 95: 507-523.

  17. Martínez JA, Fernández G, Camacho A, García F, Muñoz Erick, Osornio V, Ahumada S et al. Serum testosterone levels and late onset hypogonadism frequency. Rev Mex Urol. 2012; 72 (2): 50-55.

  18. Bassil N, Morley JE. Late-life onset hypogonadism: a review. Clin Geriatr Med. 2010; 26 (2): 197-222.

  19. Zmuda JM, Cauley JA, Kriska A. Longitudinal relations between endogenous testosterone and cardiovascular disease risk factors in middle-age men. A 13 years follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol. 1997; 146: 609-617.

  20. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM 3rd: Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000; 49: 1239–1242.

  21. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86: 724-731.

  22. Feldman HA, Longcope C, Derby CA. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002; 87: 589-598.

  23. Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. J Sex Med. 2008; 5: 998-1012.

  24. Martínez Havaloyas JM, Quepo Zaragoza A, Ferrandis Cortes C et al. Cambios en las hormonas sexuales en varones mayores de 50 años. Prevalencia de niveles bajos de testosterona y factores de riesgo. Actas Urol Esp. 2008; 32: 603-610. 

  25. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 376: 958.

  26. Álvarez E, Monteagudo G, Gómez M, Arranz C, Álvarez A, Sánchez S. Deficiencia androgénica en hombres de 60 y más años del Área de Salud Vedado. Rev Cubana Endocrinol. 2009; 20 (2): 0-0.

  27. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000; 163: 788-79

  28. Rhoden EL, Ribeiro EP, Riedner CE et al. Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. BJU Int. 2005; 95: 615-617.

  29. Zaragozá JA, Gil-Salom M, Chuan-Nuez P. Relación entre los niveles de hormonas sexuales en varones por encima de los 50 años y composición corporal, calidad ósea y calidad de vida. Actas Urol Esp. 2011; 35: 515-522.

  30. Corrales JJ, Burgo RM, Garcı´a-Berrocal B, Almeida M, Alberca I, Gonzalez-Buitrago JM, Orfao A, Miralles JM. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004; 53: 666-672.

  31. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sexsteroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf). 2006; 65: 125-131.

  32. Kapoor D, Hazel A, Clarks S, Channer KS, Jones TH. Clinical and biochemical assessment of Hypogonadism in men with type 2 diabetes. Diabetes Care. 2007; 30: 911-917.

  33. Licea Puig M, Castelo Elías-Calles L. Andropausia. Rev Cubana Endocrinol. 2006; 17.

  34. Castelo Elías-Calles L, Machado Porro M. Algunas consideraciones sobre el síndrome de PADAM. Rev Cubana Endocrinol. 2006; 17 (2).

  35. Duany NA, Hernández MG. Alcohol, función sexual y masculinidad. Rev Cubana Med Gen Integ 2012; 28 (4): 611-619.

  36. English KM, Pugh P, Parry H, Scutt N, Channer K, Jones TH. Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. Clin Sci. 2001; 100: 661–665.

  37. Hackett GI, Cole NS, Deshpande AA, Popple MD, Kennedy D, Wilkinson P. Biochemical hypogonadism in men with type 2 diabetes in primary care practice. Br J Diabetes Vasc Dis. 2009; 9: 226-231.

  38. Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol. 2005; 152: 491-499.

  39. Valles AC, Fernández GJM, Escaf S. Etiología neurógena en pacientes con disfunción eréctil. Arch Esp Urol. 2008; 61 (3).

  40. Armagan A, Kim NN, Goldstein I. Dose-response relationship between testosterone and erectile function: evidence for the existence of a critical threshold. J Androl. 2006; 27: 517– 526.

  41. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 2003; 6: 94-99.

  42. National Institute for Health and Clinical Excellence NICE guidance on Type 2 Diabetes (66). London: NICE, 2008.www.nice.org.uk/guidance/index.jsp?action=byID&o=11635. NICE. Identifying and supporting people most at risk of dying prematurely: guidance. London: NICE; 2008.

  43. Geoffrey I Hackett. Review: Androgens, erectile dysfunction and cardiovascular risk in type 2 diabetes. Br J Diabetes Vasc Dis. 2009; 9: 214-217.

  44. Gazzaruso C, Solerte SB, Pujia A. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease. J Am Coll Cardiol. 2008; 51: 2040-2044.

  45. Ma RCW, So WY, Yang XL. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol. 2008; 51: 2045-2050.

  46. Rader DJ. Effect of insulin resistance, dyslipidemia, and the intraabdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007; 120: 512- 518.

  47. Ribeiro AF, Camara C, Segre, CA, Srougi M, Serrano Jr CV. Riesgos Cardiovasculares del Bloqueo Androgénico. Arq Bras Cardiol. 2010; 95: 412-415.




2020     |     www.medigraphic.com